Tacrolimus and diabetes risk in kidney transplant patients
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study looks at how the anti-rejection drug tacrolimus (specifically Envarsus) affects blood sugar and risk of diabetes in kidney transplant patients. It aims to find out which patients might be more likely to develop glucose problems so doctors can adjust treatment early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received a kidney transplant from a living or deceased donor
- You are taking Envarsus (a specific form of tacrolimus) starting on the day of transplant or switching to it within 8 days
- You do not have diabetes (type 1 or type 2) nor high blood sugar levels that would qualify as diabetes
- This is your first kidney transplant (not a retransplant) and not a multi-organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.